Oral therapy for sickle cell disease moves closer to potential approval

Etavopivat improved hemoglobin response, reduced painful crises in Phase 3 trial

Written by Andrea Lobo, PhD |

Illustration of a new drug application, medication, laboratory vials, DNA strand, and medical charts representing the drug approval process.

Novo Nordisk has submitted applications seeking U.S. and EU approval of etavopivat, an investigational oral therapy for sickle cell disease. (Image from iStock)

Novo Nordisk has submitted applications to regulators in the U.S. and European Union seeking approval of etavopivat, its investigational oral therapy, for adults and adolescents, ages 12 and older, with sickle cell disease (SCD).

The applications were based mainly on results from the global Phase 2/3 HIBISCUS clinical trial (NCT04624659), which showed that etavopivat improved hemoglobin response and reduced the rate of painful episodes in adolescents and adults with SCD. Regulatory decisions are expected in 2027.

Recommended Reading
A large bell with the word

FDA delays decision on potential treatment for sickle cell

New oral therapy could expand sickle cell treatment options

“If approved, we are hopeful that etavopivat can provide a new disease-modifying treatment option for people living with sickle cell disease, and we will continue to work alongside the community to help advance health equity and overcome the longstanding disparities that impact those affected by this disease,” Martin Holst Lange, MD, PhD, Novo’s executive vice president, chief scientific officer, and head of research and development, said in a company press release.

SCD is caused by genetic mutations that cause the body to produce abnormal hemoglobin, the protein in red blood cells that carries oxygen throughout the body. The abnormal hemoglobin can cause red blood cells to become rigid and sickle-shaped.

These abnormal cells can block blood vessels, restricting blood flow and oxygen delivery and triggering painful vaso-occlusive crises (VOCs). They also break down faster than healthy red blood cells, leading to anemia (a shortage of healthy red blood cells).

“For people living with sickle cell disease, severe vaso-occlusive crises and other symptoms can have a profound impact on everyday life, and treatment options remain limited,” Lange said.

Etavopivat is an oral small molecule designed to activate pyruvate kinase red blood cell isozyme (PKR), an enzyme that helps red blood cells produce ATP, a molecule that provides energy needed for their survival. Activating PKR also lowers levels of 2,3-DPG, a molecule that affects how tightly hemoglobin binds to oxygen.

The experimental therapy, which Novo acquired through its purchase of Forma Therapeutics in 2022, is designed to reduce red blood cell sickling and destruction, potentially easing anemia and reducing VOCs in SCD.

Phase 3 trial shows improved hemoglobin, fewer pain crises

Etavopivat has received fast track, rare pediatric disease, and orphan drug designations in the U.S., as well as orphan drug designation in the European Union, for the treatment of people with SCD. These designations are intended to support the therapy’s clinical development and regulatory review.

The regulatory applications were supported primarily by results from the Phase 3 portion of HIBISCUS. In this part of the trial, 385 people with SCD, ages 12 to 65, were randomly assigned to receive 400 mg of etavopivat or a placebo once daily for up to one year. Participants could also continue receiving standard SCD treatments.

According to Novo Nordisk, after six months, nearly half of participants receiving etavopivat (48.7%) had an increase in hemoglobin levels of more than 1 g/dL, compared with 7.2% of those receiving the placebo. After one year, etavopivat was associated with a 27% lower annualized rate of VOCs than the placebo. The trial met both of its main goals.

Participants receiving etavopivat also went longer before experiencing their first VOC, with a median of about nine months compared with about five months for those receiving the placebo. Exploratory analyses also suggested that etavopivat-treated participants were less likely to require blood transfusions.

Novo reported that the treatment was generally well tolerated, with a safety profile consistent with earlier studies.

Additional studies exploring etavopivat’s effects in sickle cell disease

The etavopivat HIBISCUS program includes several other trials. A global Phase 3b study, called HIBISCUS 2 (NCT06612268), is testing whether etavopivat is better than a placebo at reducing VOCs. It is also evaluating the therapy’s effects on organ damage and fatigue in up to 510 people with SCD ages 12 and older.

The Phase 1/2 HIBISCUS KIDS trial (NCT06198712) is evaluating etavopivat’s safety and how it is processed by the body in up to 95 children and adolescents with SCD, ages 6 months to younger than 18 years. Participants will receive etavopivat for up to 96 weeks, or nearly two years.

The Phase 2 HIBISCUS 3 trial (NCT05953584) is studying etavopivat in adolescents with SCD who are at increased risk of stroke, which occurs when blood flow to part of the brain is blocked or reduced.

Novo is also evaluating etavopivat’s longer-term safety and effects through an open-label extension study called FLORAL (NCT06609226), which includes patients who have completed treatment in an etavopivat trial.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.